The XEC COVID-19 variant, first identified in Europe, now accounts for 45 percent of cases in the United States, according to ...

Historically, COVID-19 symptoms have been fevers or chills, cough, shortness of breath, cough, congestion or a runny nose, ...

Covid symptoms have largely stayed the same over the last few years: cough, congestion, fever, a sore throat, nausea, ...

Invivyd Inc. (NASDAQ:IVVD) announced that new in vitro neutralization data show continued neutralizing activity of Pemgarda ...

No one knows why. When virologists took their first peek at XEC, the Covid-19 variant which started to become dominant in the autumn of 2024, the early signs were ominous. The latest descendant of ...

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers for Disease ...

There have been 334 deaths attributed to COVID since July, 2024. Doctors in Massachusetts, and around the country say that ...

Invivyd (IVVD) announced that new in vitro neutralization data show continued neutralizing activity of PEMGARDA and pipeline candidate VYD2311 ...

Highlights,PEMGARDA™ shows sustained neutralizing activity against the XEC variant, covering 69% of U.S. variants.,The drug has demonstrated effectiveness against over 75% of circulating U.S. variants ...

and pipeline candidate VYD2311 against dominant SARS-CoV-2 variant XEC. As anticipated based on the structural biology of pemivibart and VYD2311, the data are largely consistent with those ...